NCT Number: NCT06242470
Phase: PHASE1
Trial Summary: The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): MacroGenics
Acronym:
A Study of MGC026 in Participants With Advanced Solid Tumors
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives